Regeneron: Initiating At These Levels

Regeneron Pharmaceuticals (REGN) has seen continued struggles after a spectacular run higher from 2010 onward. Shares rose from $25 that year to $550 late in 2015, after which they have lost half their value again in the last three years.

Situations like these, in which the valuation multiples come down amidst continued growth, always have my interest, although Regeneron was still not very cheap in the recent past, and it relies heavily on its top-selling drug EYLEA.

In February, I concluded to become a buyer if shares were to fall towards the $300 mark, with shares trading at $330 at the time. While shares have fallen below that mark, I lost sight on Regeneron, as the release of quarterly results gives me a perfect argument to revisit the thesis and indeed makes me a cautious buyer.

READ FULL ARTICLE HERE